![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CP France and JH Woods
Department of Pharmacology, University of Michigan, Ann Arbor.
Three adult, female rhesus monkeys responded under a fixed-ratio 5 schedule of stimulus-shock termination while discriminating between s.c. injections of saline and naltrexone (0.01 mg/kg). In addition, monkeys received daily injections of morphine (1.78 or 3.2 mg/kg) 3 hr before experimental sessions. With increasing doses of naltrexone monkeys switched in a dose-related manner from the saline to the naltrexone lever; complete generalization (greater than 80% responding on the naltrexone lever) occurred in all monkeys at doses of naltrexone larger than 0.0032 mg/kg. Doses of naltrexone that produced responding on the drug lever also produced effects typically observed during opioid withdrawal (e.g., miosis and salivation). Compounds with opioid mu antagonist effects under other conditions (e.g., nalorphine) substituted for naltrexone whereas a wide variety of opioid agonists (e.g., morphine, U-50,488 and butorphanol) as well as nonopioids (e.g., pentobarbital and ketamine) produced responding predominantly on the saline lever. Monkeys also switched to the naltrexone lever in a time- related manner after the daily injection of morphine with complete generalization occurring between 8 and 27 hr after morphine. Among a variety of opioid and nonopioid compounds, including drugs used in the treatment of opioid abuse (e.g., clonidine), only compounds with mu agonist actions under other conditions produced a switch in responding from the naltrexone to the saline lever in 27-hr morphine-abstinent monkeys. These results suggest single, daily injections of morphine are sufficient to produce dependence in rhesus monkeys and indicate further drug discrimination studies in morphine-treated rhesus monkeys might be pharmacologically more specific than observational procedures.
This article has been cited by other articles:
|
|
 |
|
  J.-X. Li, G. L. Becker, J. R. Traynor, Z.-H. Gong, and C. P. France Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 227 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. H. Ko, M. F. Divin, H. Lee, J. H. Woods, and J. R. Traynor Differential in Vivo Potencies of Naltrexone and 6beta-Naltrexol in the Monkey J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 772 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, M. J. Picker, A. Granger, and L. A. Dykstra Effects of Opioids in Morphine-Treated Pigeons Trained to Discriminate among Morphine, the Low-Efficacy Agonist Nalbuphine, and Saline J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. McMahon, S. L. Sell, and C. P. France Cocaine and Other Indirect-Acting Monoamine Agonists Differentially Attenuate a Naltrexone Discriminative Stimulus in Morphine-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 111 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Sell, L. R. McMahon, and C. P. France Relative Efficacy of Buprenorphine, Nalbuphine and Morphine in Opioid-Treated Rhesus Monkeys Discriminating Naltrexone J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Sell and C. P. France Cocaine and Amphetamine Attenuate the Discriminative Stimulus Effects of Naltrexone in Opioid-Dependent Rhesus Monkeys J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1103 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Brandt, S. S. Negus, N. K. Mello, M. S. Furness, X. Zhang, and K. C. Rice Discriminative Stimulus Effects of the Nonpeptidic delta -Opioid Agonist SNC80 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1157 - 1164. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Brandt and C. P. France Chronic l-Alpha Acetylmethadol in Rhesus Monkeys: Discriminative Stimulus and Other Behavioral Measures of Dependence and Withdrawal J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1029 - 1037. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. D. Green, G. Bélanger, D. W. Hum, A. Bélanger, and T. R. Tephly Glucuronidation of Opioids, Carboxylic Acid-Containing Drugs, and Hydroxylated Xenobiotics Catalyzed by Expressed Monkey UDP-Glucuronosyltransferase 2B9 Protein Drug Metab. Dispos., December 1, 1997; 25(12): 1389 - 1394. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Brandt, S. R. Cabansag, and C. P. France Discriminative Stimulus Effects of l-alpha -Acetylmethadol (LAAM), Buprenorphine and Methadone in Morphine-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 574 - 584. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Paronis and J. H. Woods Ventilation in Morphine-Maintained Rhesus Monkeys. I: Effects of Naltrexone and Abstinence-Associated Withdrawal, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 348 - 354. [Abstract] [Full Text]
|
|
|
|
|
|
C. A. Paronis and J. H. Woods Ventilation in Morphine-Maintained Rhesus Monkeys. II: Tolerance to the Antinociceptive But Not the Ventilatory Effects of Morphine, J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 355 - 362. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
